These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 1730121)

  • 1. Treatment of relapsed or refractory adult acute lymphocytic leukemia.
    Freund M; Diedrich H; Ganser A; Gramatzki M; Heil G; Heyll A; Henke M; Hiddemann W; Haas R; Kuse R
    Cancer; 1992 Feb; 69(3):709-16. PubMed ID: 1730121
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of relapsed acute lymphocytic leukemia in adults.
    Freund M; De Boben M; Diedrich H; Ganser A; Heil G; Heyll A; Henke M; Hiddemann W; Knauf U; Koch P
    Haematol Blood Transfus; 1990; 33():432-6. PubMed ID: 2182434
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of adults with acute lymphoblastic leukaemia in first bone marrow relapse: results of the ALL R-87 protocol.
    Giona F; Annino L; Rondelli R; Arcese W; Meloni G; Testi AM; Moleti ML; Amadori S; Resegotti L; Tabilio A; Ladogana S; Fioritoni G; Camera A; Liso V; Leoni P; Mandelli F
    Br J Haematol; 1997 Jun; 97(4):896-903. PubMed ID: 9217194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Successful treatment of adult acute lymphoblastic leukemia after relapse with prednisone, intermediate-dose cytarabine, mitoxantrone, and etoposide (PAME) chemotherapy.
    Milpied N; Gisselbrecht C; Harousseau JL; Sebban C; Witz F; Troussard X; Gratecos N; Michallet M; LeBlond V; Auzanneau G
    Cancer; 1990 Aug; 66(4):627-31. PubMed ID: 2386891
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized trial of induction therapy (daunorubicin, vincristine, prednisone versus daunorubicin, vincristine, prednisone, cytarabine and 6-thioguanine) in adult acute lymphoblastic leukemia with long-term follow-up: an Eastern Cooperative Oncology Group Study (E3486).
    Wiernik PH; Cassileth PA; Leong T; Hoagland HC; Bennett JM; Paietta E; Oken MM;
    Leuk Lymphoma; 2003 Sep; 44(9):1515-21. PubMed ID: 14565653
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intermediate-dose Ara-C/m-AMSA for remission induction and high-dose Ara-C/m-AMSA for intensive consolidation in relapsed and refractory adult acute myelogeneous leukemia.
    Jehn U; Heinemann V
    Haematol Blood Transfus; 1990; 33():333-8. PubMed ID: 1691134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intensive sequential chemotherapy with mitoxantrone and continuous infusion etoposide and cytarabine for previously treated acute myelogenous leukemia.
    Archimbaud E; Leblond V; Michallet M; Cordonnier C; Fenaux P; Travade P; Dreyfus F; Jaubert J; Devaux Y; Fiere D
    Blood; 1991 May; 77(9):1894-900. PubMed ID: 2018832
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Adult acute lymphoblastic leukemia: preliminary results of the LAL-86 protocol].
    Ribera JM; Grañena A; Rozman C; Urbano-Ispizua A; Bladé J; Carreras E; Cervantes F; Marín P; Sierra J; Nomdedeu B
    Sangre (Barc); 1990 Feb; 35(1):26-32. PubMed ID: 2333581
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel multiagent chemotherapy for bone marrow relapse of pediatric acute lymphoblastic leukemia.
    Leahey AM; Bunin NJ; Belasco JB; Meek R; Scher C; Lange BJ
    Med Pediatr Oncol; 2000 May; 34(5):313-8. PubMed ID: 10797352
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estimated 6-year event-free survival of 55% in 60 consecutive adult acute lymphoblastic leukemia patients treated with an intensive phase II protocol based on high induction dose of daunorubicin.
    Todeschini G; Tecchio C; Meneghini V; Pizzolo G; Veneri D; Zanotti R; Ricetti MM; Solero P; April F; Perona G
    Leukemia; 1998 Feb; 12(2):144-9. PubMed ID: 9519775
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Daunorubicin continuous infusion induces more toxicity than bolus infusion in acute lymphoblastic leukemia induction regimen: a randomized study.
    Hunault-Berger M; Milpied N; Bernard M; Jouet JP; Delain M; Desablens B; Sadoun A; Guilhot F; Casassus P; Ifrah N
    Leukemia; 2001 Jun; 15(6):898-902. PubMed ID: 11417474
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination chemotherapy of intermediate-dose cytarabine, idarubicin, plus etoposide and subsequent mobilized donor leukocyte infusion for relapsed acute leukemia after allogeneic bone marrow transplantation.
    Lee JH; Lee KH; Kim S; Seol M; Kim SH; Kim WK; Lee JS
    Leuk Res; 2001 Apr; 25(4):305-12. PubMed ID: 11248327
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aggressive chemotherapy for acute leukemia relapsed after bone marrow transplantation: a second chance?
    Sica S; Di Mario A; Pagano L; Etuk B; Salutari P; Leone G
    Acta Haematol; 1992; 87(4):173-5. PubMed ID: 1519431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of intensive postremission chemotherapy for adults with acute nonlymphocytic leukemia using high-dose cytosine arabinoside with L-asparaginase and amsacrine with etoposide.
    Tallman MS; Appelbaum FR; Amos D; Goldberg RS; Livingston RB; Mortimer J; Weiden PL; Thomas ED
    J Clin Oncol; 1987 Jun; 5(6):918-26. PubMed ID: 3585446
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bone marrow transplantation for advanced acute leukemia: a pilot study of high-energy total body irradiation, cyclophosphamide and continuous infusion etoposide.
    Bostrom B; Weisdorf DJ; Kim T; Kersey JH; Ramsay NK
    Bone Marrow Transplant; 1990 Feb; 5(2):83-9. PubMed ID: 2107007
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Salvage therapy for relapsed or refractory childhood acute lymphocytic leukemia by alternative administration a lymphoid- and myeloid-directed chemotherapeutic regimen consisting of dual modulation of ara-C, hydroxyurea, and etoposide.
    Higashigawa M; Hori H; Hirayama M; Kawasaki H; Ido M; Azuma E; Sakurai M
    Leuk Res; 1997 Sep; 21(9):811-5. PubMed ID: 9393595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Probability of long-term disease-free survival for acute myeloid leukemia patients after first relapse: A single-centre experience.
    Vignetti M; Orsini E; Petti MC; Moleti ML; Andrizzi C; Pinto RM; Amadori S; Meloni G
    Ann Oncol; 1996 Nov; 7(9):933-8. PubMed ID: 9006744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo purging with high-dose cytarabine followed by high-dose chemoradiotherapy and reinfusion of unpurged bone marrow for adult acute myelogenous leukemia in first complete remission.
    Stein AS; O'Donnell MR; Chai A; Schmidt GM; Nademanee A; Parker PM; Smith EP; Snyder DS; Molina A; Stepan DE; Spielberger R; Somlo G; Margolin KA; Vora N; Lipsett J; Lee J; Niland J; Forman SJ
    J Clin Oncol; 1996 Aug; 14(8):2206-16. PubMed ID: 8708709
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intermediate-dose Ara-C/m-AMSA for remission induction and high-dose Ara-C/m-AMSA for intensive consolidation in relapsed and refractory adult acute myelogenous leukemia (AML).
    Jehn U; Heinemann V; Wilmanns W
    Anticancer Res; 1989; 9(1):119-24. PubMed ID: 2705739
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Idarubicin and high-dose cytarabine in the treatment of refractory and relapsed acute lymphoblastic leukemia.
    Giona F; Testi AM; Amadori S; Meloni G; Carotenuto M; Resegotti L; Colella R; Leoni P; Carella AM; Grotto P
    Ann Oncol; 1990; 1(1):51-5. PubMed ID: 2078485
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.